Send us a textSteve Lydeamore, CEO of Immuron Limited, takes us behind the scenes of one of Australia's most innovative biopharmaceutical companies. What makes this Melbourne-based biotech unique is their dual focus—a thriving commercial product alongside a promising technology platform targeting infectious diseases.The spotlight falls on Travelan, Immuron's preventative treatment for traveller's diarrhoea that has experienced phenomenal growth. After sales plummeted to near-zero during the pandemic, the company has ssen a remarkable turnaround from $145,000 to over $5.3 million in less than a year. This success story involved strengthening pharmacy distribution networks across Australia and Canada while leveraging Amazon as their primary channel in the US market. As international travel rebounds, particularly to high-risk regions like Bali and Vietnam, Travelan's unique preventative approach—"nobody wants to get it"—positions it perfectly for continued growth.

Ver todos los episodios